Healthcare

Image

Global Drug-Device Combination Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Report
  • Feb 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Drug-Device Combination Market, By Product (Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens and Others, Application Type (Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, and Others), End User (Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others) – Industry Trends and Forecast to 2031.

Drug-Device Combination Market

Drug-Device Combination Market Analysis and Size

Government health organizations, particularly the U.S. FDA's Office of Combination Products, play a crucial role in ensuring patient safety by regulating drug-device combination products. This initiative addresses challenges and ensures consistent and effective regulation. In response to increasing demand, multinational pharmaceutical companies are anticipated to accelerate the development of clinical medications and devices, focusing on advanced medication delivery systems.                                

Data Bridge Market Research analyses that the global drug-device combination market which was USD 15,633.36 million in 2023, is expected to reach USD 34,002.04 million by 2031, and is expected to undergo a CAGR of 10.2% during the forecast period of 2024 to 2031. This indicates that the market value. “Auto-injector” dominates the product segment of the global drug-device combination market owing to the growing global demand for medical devices catering to patient treatment needs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Drug-Device Combination Market Scope and Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

 Product (Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens and Others), Application Type (Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, and Others), End User (Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Medtronic (Ireland), Zimmer Biomet (U.S.), Amgen Inc. (U.S.), MediPrint (U.S.), Propeller Health (U.S.), BD (U.S.), CosMED Pharmaceutical Co., Ltd (Japan), Micron Biomedical, Inc.(U.S.), Findair Sp. z o. o. (Poland), MetP Pharma AG (Switzerland), SONCEBOZ (Switzerland), Eitan Medical (Israel), Vaxess Technologies Inc. (U.S.), UBCUJECT Aps (Denmark), E3D Elcam Drug[JS3]  Delivery Devices (Israel) OcuMedic  (U.S.),   GlaxoSmithKline plc (U.K.), Bayer AG (Germany), NanoPass  (Israel),  Sensirion AG Switzerland (Switzerland), Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)  (U.S.), Insulet Corporation (U.S.), TheraJect (U.S.), Otsuka America Pharmaceutical, Inc.  (U.S.), Raphas Co., Ltd.  (South Korea), EOFLOW CO., LTD.  (South Korea), CGbio  (South Korea)

Market Opportunities

  • Advancements in Personalized Medicine
  • Patient-Centric Approaches
  • Technological Innovation

Market Definition

A drug-device combination refers to a product that combines a pharmaceutical substance with a medical device, aiming to enhance treatment efficacy or delivery. These products, such as drug-eluting stents or inhalers, integrate drugs and devices to provide targeted therapy, improved patient outcomes, and enhanced delivery mechanisms in medical treatments.

Drug-Device Combination Market Dynamics

Drivers

  • Increasing prevalence of chronic disease

The surge in chronic diseases drives the drug-device combination market by prompting the creation of integrated solutions. These combinations deliver superior therapeutic outcomes, addressing specific patient needs and contributing to an evolving treatment landscape for chronic conditions. This dynamic response to healthcare challenges underscores the growing significance of innovative, integrated approaches in disease management.

  • Demand for minimally invasive therapies

The increasing demand for minimally invasive therapies propels the drug-device combination market by fostering the creation of products with targeted and efficient delivery mechanisms. This preference reflects a growing trend towards less invasive treatment options, driving innovation in drug-device combinations to enhance therapeutic effectiveness while minimizing patient discomfort and recovery times.

Opportunities

  • Rising aging population

The rising global aging population creates a substantial market opportunity for drug-device combinations, as elderly individuals demand targeted and efficient healthcare solutions. These innovative combinations cater to the unique needs of aging patients, addressing age-related health challenges and positioning the market as a crucial player in geriatric care.

  • Market Expansion in Emerging Economies

Market expansion in emerging economies presents a significant opportunity for the drug-device combination market. Growing healthcare infrastructure in these regions creates a favorable environment, fostering increased adoption and accessibility of innovative drug-device combinations. This expansion aligns with the rising demand for advanced healthcare solutions, driving market growth and penetration.

Restraints/Challenges

  • Regulatory complexity

Regulatory complexity hampers the drug-device combination market by creating hindrence in navigating intricate and evolving frameworks. Compliance with both pharmaceutical and medical device regulations adds complexity, impacting the approval process and hindering the seamless development and commercialization of these innovative products.

  • Risk of Uncertain Classification

The risk of uncertain classification poses a challenge in the drug-device combination market, complicating regulatory pathways and approval processes. Ambiguities in determining the appropriate classification for these products create uncertainties, potentially delaying market entry and hindering manufacturers' ability to navigate regulatory requirements effectively.

This global drug-device combination market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In August 2022, Medtronic introduced its newest drug-eluting coronary stent, the Onyx Frontier drug-eluting stent (DES). The DES combines the best-in-class stent platform with an improved delivery mechanism to improve deliverability and acute performance in the most difficult patients
  • In August 2022, Terumo Corporation introduced 'G-Lasta Subcutaneous Injection 3.6 mg BodyPod,' a drug-device combination developed with Kyowa Kirin Co., Ltd. Approved by Japan's Ministry of Health, Labour, and Welfare, this innovative product showcases collaboration in delivering advanced healthcare solutions, further expanding the market for effective drug-device combinations
  • In November 2021, Becton, Dickinson, and Company introduced the BD UltraSafe Plus 2.25 mL Passive Needle Guard in drug-device combination products. The BD UltraSafe Plus 2.25 mL system, when paired with a prefillable syringe, allows for the subcutaneous delivery of biologic solutions with viscosities up to 30 cP and fill volumes up to 2 mL
  • In August 2021, SINOMED announced the first commercial implantation of the HT Supreme Drug-Eluting Stent (DES) at University Hospital Galway in conjunction with the National University of Ireland Galway (NUI Galway), kicking off the European rollout. This will most likely aid interventional cardiologists in treating patients with coronary artery disease (CAD) who have narrow arteries that are generally untreatable during percutaneous coronary intervention (PCI) with larger stent technology

Global Drug-Device Combination Market Scope

The global drug-device combination market is segmented on the basis of product, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Auto-Injector
  • Microneedle Patch
  • Digital Pill
  • Smart Inhaler
  • Drug Delivery Hydrogels
  • Drug-Eluting Lens
  • Others

 Application Type

  • Orthopedic Diseases
  • Respiratory Diseases
  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Others

 End User

  • Clinics
  • Hospitals
  • Home Care Settings
  • Ambulatory Care Centers
  • Others

 Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

Drug-Device Combination Market Regional Analysis/Insights

The global drug-device combination market is analysed and market size insights and trends are provided by country, product, application, end user, and distribution channel as referenced above.

The countries covered in the global drug-device combination market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is projected to secure a substantial market share in the global drug-device combination market. This is attributed to the region's robust healthcare infrastructure, heightened awareness of drug-device combinations, and their widespread adoption. The prevalence of chronic cases further fuels the market's growth, making North America a key player in this evolving healthcare landscape.

Asia-Pacific is the fastest-growing market in the global drug-device combination market from 2024 to 2031. Fueled by a large population, growing technology adoption, demand for personalized medicine, and a rising incidence of chronic diseases, the region experiences substantial expansion, making it a pivotal player in the evolving landscape of drug-device combination products.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The global drug-device combination market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global drug-device combination market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global drug-device combination market. The data is available for historic period 2016-2021.

Competitive Landscape and Drug-Device Combination Market Share Analysis

The global drug-device combination market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global drug-device combination market.

Some of the major players operating in the global drug-device combination market are:

  • Medtronic (Ireland)
  • Zimmer Biomet (U.S.)
  •  Amgen Inc. (U.S.)
  •  MediPrint (U.S.)
  •  Propeller Health (U.S.)
  •  BD (U.S.)
  • CosMED Pharmaceutical Co., Ltd (Japan)
  • Micron Biomedical, Inc.(U.S.)
  •  Findair Sp. z o. o. (Poland)
  •  MetP Pharma AG (Switzerland)
  •  SONCEBOZ (Switzerland)
  •  Eitan Medical (Israel)
  • Vaxess Technologies Inc. (U.S.)
  •  UBCUJECT Aps (Denmark)
  •  E3D Elcam Drug Delivery Devices (Israel)
  • OcuMedic(U.S.)
  •  GlaxoSmithKline plc (U.K.)
  •  Bayer AG (Germany)
  •  NanoPass  (Israel)
  •   Sensirion AG Switzerland (Switzerland)
  •  Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) (U.S.)
  •  Insulet Corporation (U.S.)
  • TheraJect (U.S.)
  •  Otsuka America Pharmaceutical, Inc.  (U.S.)
  •  Raphas Co., Ltd.  (South Korea)
  •  EOFLOW CO., LTD.  (South Korea)
  • CGbio  (South Korea)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The drug-device combination market size will be worth USD 34,002.04 million by 2031.
The growth rate of the drug-device combination market is 10.2% during the forecast period by 2031.
The increasing prevalence of chronic disease & demand for minimally invasive therapies are the growth drivers of the drug-device combination market.
Product, application, end user, and distribution channel are the factors on which the drug-device combination market research is based.
Major companies in the drug-device combination market are Medtronic (Ireland), Zimmer Biomet (U.S.), Amgen Inc. (U.S.), MediPrint (U.S.), Propeller Health (U.S.), BD (U.S.), CosMED Pharmaceutical Co., Ltd (Japan), Micron Biomedical, Inc.(U.S.), Findair Sp. z o. o. (Poland), MetP Pharma AG (Switzerland), SONCEBOZ (Switzerland), Eitan Medical (Israel), Vaxess Technologies Inc. (U.S.), UBCUJECT Aps (Denmark), E3D Elcam Drug[JS3] Delivery Devices (Israel) OcuMedic (U.S.), GlaxoSmithKline plc (U.K.), Bayer AG (Germany), NanoPass (Israel), Sensirion AG Switzerland (Switzerland), Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) (U.S.), Insulet Corporation (U.S.), TheraJect (U.S.), Otsuka America Pharmaceutical, Inc. (U.S.), Raphas Co., Ltd. (South Korea), EOFLOW CO., LTD. (South Korea), CGbio (South Korea).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials